BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 20186820)

  • 1. Cumulative evaluation of a quantitative immunochemical fecal occult blood test to determine its optimal clinical use.
    Rozen P; Comaneshter D; Levi Z; Hazazi R; Vilkin A; Maoz E; Birkenfeld S; Niv Y
    Cancer; 2010 May; 116(9):2115-25. PubMed ID: 20186820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of colorectal adenomas by a quantitative immunochemical faecal occult blood screening test depends on adenoma characteristics, development threshold used and number of tests performed.
    Rozen P; Levi Z; Hazazi R; Waked A; Vilkin A; Maoz E; Birkenfeld S; Leshno M; Niv Y
    Aliment Pharmacol Ther; 2009 Apr; 29(8):906-17. PubMed ID: 19183147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical, fecal occult blood screening test.
    Vilkin A; Rozen P; Levi Z; Waked A; Maoz E; Birkenfeld S; Niv Y
    Am J Gastroenterol; 2005 Nov; 100(11):2519-25. PubMed ID: 16279909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative colonoscopic evaluation of relative efficiencies of an immunochemical faecal occult blood test and a sensitive guaiac test for detecting significant colorectal neoplasms.
    Rozen P; Levi Z; Hazazi R; Waked A; Vilkin A; Maoz E; Birkenfeld S; Niv Y
    Aliment Pharmacol Ther; 2009 Feb; 29(4):450-7. PubMed ID: 19035980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can patients at high risk for significant colorectal neoplasms and having normal quantitative faecal occult blood test postpone elective colonoscopy?
    Hazazi R; Rozen P; Leshno M; Levi Z; Samuel Z; Waked A; Vilkin A; Maoz E; Birkenfeld S; Niv Y
    Aliment Pharmacol Ther; 2010 Feb; 31(4):523-33. PubMed ID: 19925498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can quantification of faecal occult blood predetermine the need for colonoscopy in patients at risk for non-syndromic familial colorectal cancer?
    Levi Z; Rozen P; Hazazi R; Vilkin A; Waked A; Maoz E; Birkenfeld S; Niv Y
    Aliment Pharmacol Ther; 2006 Nov; 24(10):1475-81. PubMed ID: 17032281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chemical or immunological tests for the detection of fecal occult blood in colorectal cancer screening?].
    Quintero E
    Gastroenterol Hepatol; 2009 Oct; 32(8):565-76. PubMed ID: 19577340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitivity, but not specificity, of a quantitative immunochemical fecal occult blood test for neoplasia is slightly increased by the use of low-dose aspirin, NSAIDs, and anticoagulants.
    Levi Z; Rozen P; Hazazi R; Vilkin A; Waked A; Maoz E; Birkenfeld S; Lieberman N; Klang S; Niv Y
    Am J Gastroenterol; 2009 Apr; 104(4):933-8. PubMed ID: 19293792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon.
    Lieberman DA; Weiss DG;
    N Engl J Med; 2001 Aug; 345(8):555-60. PubMed ID: 11529208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for familial colorectal cancer with a sensitive immunochemical fecal occult blood test: a pilot study.
    Gimeno-García AZ; Quintero E; Nicolás-Pérez D; Hernández-Guerra M; Parra-Blanco A; Jiménez-Sosa A
    Eur J Gastroenterol Hepatol; 2009 Sep; 21(9):1062-7. PubMed ID: 19307978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of a desk top instrument for the automated development and immunochemical quantification of fecal occult blood.
    Rozen P; Waked A; Vilkin A; Levi Z; Niv Y
    Med Sci Monit; 2006 Jun; 12(6):MT27-32. PubMed ID: 16733493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia.
    de Wijkerslooth TR; Stoop EM; Bossuyt PM; Meijer GA; van Ballegooijen M; van Roon AH; Stegeman I; Kraaijenhagen RA; Fockens P; van Leerdam ME; Dekker E; Kuipers EJ
    Am J Gastroenterol; 2012 Oct; 107(10):1570-8. PubMed ID: 22850431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Colonoscopy: a review of its yield for cancers and adenomas by indication.
    Rex DK
    Am J Gastroenterol; 1995 Mar; 90(3):353-65. PubMed ID: 7872270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.
    Allison JE; Sakoda LC; Levin TR; Tucker JP; Tekawa IS; Cuff T; Pauly MP; Shlager L; Palitz AM; Zhao WK; Schwartz JS; Ransohoff DF; Selby JV
    J Natl Cancer Inst; 2007 Oct; 99(19):1462-70. PubMed ID: 17895475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter prospective study of immunochemical fecal occult blood testing for colorectal cancer detection.
    Lohsiriwat V; Thavichaigarn P; Awapittaya B
    J Med Assoc Thai; 2007 Nov; 90(11):2291-5. PubMed ID: 18181309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Follow-up of patients undergoing both semiquantitated immunochemical fecal occult blood and colonoscopy examinations.
    Rozen P; Liphshitz I; Barchana M
    Eur J Cancer Prev; 2012 May; 21(3):247-53. PubMed ID: 21955798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic performance of quantitative fecal immunochemical test and multivariate prediction model for colorectal neoplasms in asymptomatic individuals.
    Omata F; Shintani A; Isozaki M; Masuda K; Fujita Y; Fukui T
    Eur J Gastroenterol Hepatol; 2011 Nov; 23(11):1036-41. PubMed ID: 21897207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative immunochemical fecal occult blood testing for colorectal adenoma detection: evaluation in the target population of screening and comparison with qualitative tests.
    Haug U; Hundt S; Brenner H
    Am J Gastroenterol; 2010 Mar; 105(3):682-90. PubMed ID: 19953091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A quantitative immunochemical faecal occult blood test is more efficient for detecting significant colorectal neoplasia than a sensitive guaiac test.
    Levi Z; Hazazi R; Rozen P; Vilkin A; Waked A; Niv Y
    Aliment Pharmacol Ther; 2006 May; 23(9):1359-64. PubMed ID: 16629942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fecal occult blood test for colorectal cancer screening: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2009; 9(10):1-40. PubMed ID: 23074514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.